Craft

Evolus

Stock Price

$16.7

2024-10-29

Market Capitalization

$1.1 B

2024-10-29

Revenue

$297.2 M

FY, 2025

Evolus Summary

Company Summary

Overview
Evolus is a medical aesthetics company focused on providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market.
Type
Public
Status
Active
Founded
2014
HQ
Newport Beach, CA, US | view all locations
Website
https://www.evolus.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • David Moatazedi

    David Moatazedi, President, CEO, Director

  • Vikram Malik

    Vikram Malik, Chairman of the Board of Directors

  • Kurt Knab
  • Rui Avelar

    Rui Avelar, Chief Medical Officer and Head of Research and Development

LocationsView all

1 location detected

  • Newport Beach, CA HQ

    United States

    520 Newport Center Dr #1200

Evolus Financials

Summary Financials

Revenue (Q1, 2026)
$73.1M
Gross profit (Q1, 2026)
$48.9M
Net income (Q1, 2026)
($10.7M)
Cash (Q1, 2026)
$49.8M
EBIT (Q1, 2026)
($6.8M)
Enterprise value
$1.2B

Footer menu